Therefore, a broad compound screen containing 128 compounds which target different epigenetic key players (including histone deacetylases (HDACs), sirtuins (SIRTs), histone demethylases (HDMs), histone acetyltransferases (HATs), histone methyltransferases (HMTs), and DNA methyltransferases (DNMTs)) was performed on IDH wild type and mutant chondrosarcoma cell lines to explore whether these epigenetic changes can be used as a target for novel anti-cancer therapy. The gene discussed is IDH2; the disease is chondrosarcoma.